CRAD B C-RAD AB

C-RAD has appointed Henrik Bergentoft as new CFO

C-RAD has appointed Henrik Bergentoft as new CFO

Press release 2019-11-22

C-RAD today announces that Henrik Bergentoft has been appointed Chief Financial Officer effective March 1, 2020.

Henrik has an extensive experience of leading positions within finance, primarily in publicly listed companies. He is currently CFO at MSAB (publ.), a position he has held for three years. Prior to that, he has held positions as CFO and Finance Director at Aerocrine AB, Nordkom AB, and ContextVision AB. Henrik holds a master’s degree in International Business from the Uppsala University.

“We are pleased to welcome Henrik to our management team as our CFO. Henriks’s very broad financial experience will be of great value for C-RAD as the company enters a new phase of growth. I am very much looking forward to work closely with Henrik to execute our growth strategy” says Tim Thurn, CEO C-RAD AB.

“I am very excited joining C-RAD to support the growth journey ahead, as well as being part of a company with important contribution to cancer treatment”, says Henrik Bergentoft.

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Device Co Ltd in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit -rad.com

For further information:

Tim Thurn, CEO C-RAD AB, Phone , Email

Attachment

EN
22/11/2019

Underlying

CRAD BC-RAD AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C-RAD AB

Free Trial
CRAD B C-RAD AB

C-Rad AB: 1 director

A director at C-Rad AB bought 8,000 shares at 32.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

03/10/23 March 10, 2023 1 EN
Erik Cassel
  • Erik Cassel
GETI B Getinge AB Clas...
PHO PHOTOCURE ASA ... (+37)

Sector Fast Comment - Hospital data update

Better hospital margins in September Weaker procedure volume momentum into Q4 Small positive for capex exposure

GETI B GETINGE AB CLASS B
PHO PHOTOCURE ASA
DEMANT DEMANT A/S
OSSR OSSUR HF.
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
GN GN STORE NORD A/S
ALK B ALK-ABELLO A/S CLASS B
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
VICO VICORE PHARMA HOLDING AB
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
VITR VITROLIFE AB
MCAP MEDCAP
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
OSSD OSSDSIGN
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
VIMIAN VIMIAN GROUP AB
LUND B H. LUNDBECK A/S
11/09/22 November 9, 2022 1 EN
Erik Cassel
  • Erik Cassel
CRAD B C-RAD AB

C-RAD AB - Resilient despite weaker end markets

Exceptional Q3 sales and EBIT, but orders came in weak We cut ’24e EBIT by 3% on end-market weakness Fair value range of SEK 45-95/share

10/30/22 October 30, 2022 1 EN
Erik Cassel
  • Erik Cassel
GETI B Getinge AB Clas...
PHO PHOTOCURE ASA ... (+10)

Sector Fast Comment - Hospital data update

Better hospital margins in August Congress passed supportive spending bill Small positive for companies with capex exposure

GETI B GETINGE AB CLASS B
PHO PHOTOCURE ASA
CRAD B C-RAD AB
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
MCAP MEDCAP
OSSD OSSDSIGN
10/04/22 October 4, 2022 1 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke
CRAD B C-RAD AB

C-RAD AB - Record heat on orders beat

Remarkable order intake 35% better than ABGSCe ‘23e EBIT up 8% and ‘24e up 4% Fair value range of SEK 45-95/share

07/21/22 July 21, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch